August 14th, 2009

The U.S. Food and Drug Administration (FDA) has approved Saphris tablets (asenapine) to treat adults with schizophrenia or bipolar disorder.
"Mental illnesses like schizophrenia and bipolar disorder can be ...
August 6th, 2009

Last week, the U.S. Food and Drug Administration (FDA) handed down two new approvals for Invega (paliperidone), an atypical antipsychotic medication, for the treatment of schizoaffective disorder, and ...
July 20th, 2009

A once-daily form of trazodone, a second-generation antidepressant that has been available for the treatment of depression for decades, has been rejected by the U.S. Food ...
July 1st, 2009

The U.S. Food and Drug Administration today announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking ...
June 15th, 2009

The U.S. Food and Drug Administration (FDA) urged caution on interpreting the findings from a new study published on Monday that showed an increase in ...
June 10th, 2009

Three atypical antipsychotics -- Seroqiel, Geodon, and Zyprexa -- were voted to be “acceptably safe” and effective for the treatment of schizophrenia ...
June 10th, 2009

Seroquel was voted to be "acceptably safe" and effective for the treatment of schizophrenia in teenagers, said a U.S. Food and Drug Administration (FDA) panel of outside ...
June 2nd, 2009

A review of a government decision to issue a warning for children taking antidepressants suggests unintended consequences.
Government warnings about suicidality among children taking antidepressants appear to be associated with ...
May 18th, 2009

Risperdal Consta (risperidone), a drug already approved in the treatment of schizophrenia, has received approval by the U.S. Food and Drug Administration (FDA) for the treatment of bipolar I disorder. ...
May 7th, 2009

The U.S. Food and Drug Administration (FDA) yesterday approved a new psychiatric medication for the treatment of adults with schizophrenia called Fanapt (iloperidone).
Fanapt (iloperidone) is a mixed dopamine ...